Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients.

Pediatrics international : official journal of the Japan Pediatric Society - 1 Aug 2005

Ni Yen-Hsuan, Huang Fu-Chen, Wu Tzee-Chung, Kong Man-Shan, Jeng Yung-Ming, Chen Pei-Jer, Tsuei Daw-Jen, Chen Huey-Ling, Hsu Hong-Yuan, Chang Mei-Hwei

Abstract excerpt

BACKGROUND: Lamivudine treatment in chronic carriers who acquired hepatitis B virus through maternal transmission were investigated. METHODS: A total of 29 subjects (Male:Female, 24:5; mean age, 14.7 +/- 5.6 years) who were hepatitis B e antigen (HBeAg) seropositive for >6 months, alanine aminotr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Child, Preschool
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Infectious Disease Transmission, Vertical

Share to Lamivudine

Share to Polymerase Chain Reaction

Source

Identifiers

PMID: 16091071
DOI: 10.1111/j.1442-200x.2005.02101.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16091071-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients.PMID 16091071Read ↗

Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.Semantic proximity Read ↗

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.Semantic proximity Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.Semantic proximity Read ↗

[Lamivudine therapy for chronic hepatitis B].Semantic proximity Read ↗

HBV mutations associated with lamivudine therapy.Semantic proximity Read ↗

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.Semantic proximity Read ↗

Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.Semantic proximity Read ↗

Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.Semantic proximity Read ↗

[Treatment of chronic viral hepatitis B with lamivudine].Semantic proximity Read ↗

Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

[Clinical efficacy of lamivudine in the treatment of chronic hepatitis B].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.